

The Bulletin

This monthly bulletin includes recent changes to our medical and reimbursement policies.

Notes

- *The Bulletin* is a supplement to our bimonthly provider newsletter, [*The Connection*](#).
 - Medication policy updates are published in *The Connection*.
- Dental policy updates are published in the News section of asurisdental.com/providers.

Medical policies

Commercial

Changes effective October 1, 2025

Durable Medical Equipment

- Definitive Lower Limb Prostheses (#18)
 - Clarified that when prior prosthesis use is applicable, providers should:
 - Define ordering practitioner, and
 - Include examples of validated functional-level assessment tools
- Negative Pressure Wound Therapy in the Outpatient Setting (#42)
 - Clarified policy criteria

Genetic Testing

- Evaluating the Utility of Genetic Panels (#64)
 - Added seven panel tests to the policy
 - Removed four tests from the policy

Laboratory

- Circulating Tumor-Tissue Modified Viral DNA Testing for Cancer Management (#82)
 - New policy
 - Moved codes with no change to existing edit from the *Circulating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor Cancers* (Laboratory #46) medical policy
- Investigational Gene Expression, Biomarker, and Multianalyte Testing (#77)
 - Added the following tests to the policy:
 - PromarkerD, iDart™ Lyme IgG ImmunoBlot Kit
 - PancreaSure tests
- Laboratory Tests for Organ Transplant Rejection (#51)
 - Updated policy to address:
 - Donor-derived cell-free DNA testing and gene expression profiling for liver transplant
 - Non-HLA antibody testing for organ transplant
- Multimarker and Proteomics-based Serum Testing Related to Ovarian Cancer (#60)
 - Updated criteria to address testing more generally

Surgery

- Radiofrequency and Ultrasound Ablation of the Renal Sympathetic Nerves as a Treatment for Uncontrolled Hypertension (#235)
 - Added criteria for ablation of renal sympathetic nerves

Changes effective January 1, 2026

Utilization Management

- Surgical Site of Care – Colonoscopy (#20)
 - New policy specific to colonoscopy; colonoscopies are currently addressed in the *Surgical Site of Care – Hospital Outpatient* (#19) medical policy, which will be updated January 1, 2026, to align with implementation of this new policy

Surgery

- Surgical Treatments for Lymphedema and Lipedema (#220)
 - Clarifying clinical examination and diagnostic documentation requirements

[View our commercial
Medical Policy Manual](#)

Medicare Advantage

Changes effective October 1, 2025

Genetic Testing

- Genetic and Molecular Diagnostics – Next Generation Sequencing, Genetic Panels, and Biomarker Testing (#64)
 - Removed testing that is now addressed in new policies
- Genetic and Molecular Diagnostics – Testing for Cancer Diagnosis, Prognosis, and Treatment Selection (#83)
 - Updated the policy in alignment with the 2025 Q4 code update and updated Medicare guidance
- Molecular Panel Testing for Identification of Microorganisms (#85)
 - New policy
- Pharmacogenomic (PGx) Testing (#10)
 - New policy

Laboratory

- Biomarkers for Cardiovascular Disease (#78)
 - New policy
- Laboratory Tests for Organ Transplant Rejection (#51)
 - New policy

[View our Medicare Advantage
Medical Policy Manual](#)

Join our medical policy discussion

We encourage input as policies are developed, but we also have a formal process that allows you to submit additional information—such as well-designed, published clinical trials—that may warrant a policy review. To share your feedback about our medical policies, join our [reviewer list](#).

Recent updates and archived medical policies

We encourage you to review [recent updates and archived medical policies](#), which may also include revisions that will be published in the next issue of *The Bulletin*.

Reimbursement policies

Changes effective January 1, 2026

Administrative

- Hearing Aid and Supplies (#152)—applies to commercial
 - Changing policy title; policy was previously titled *Hearing Aid Supplies*
 - Adding billing guidance for upgrades to deluxe hearing aids; guidance addresses HCPCS code S1001 and the need for a non-covered services consent form
- Non-Reimbursable Services (#107)—applies to commercial and Medicare Advantage
 - **Commercial lines of business only:** Adding evaluation and management (E&M) visit complexity add-on code HCPCS G2211 as a non-reimbursable service (NRS)
- Timely Receipt of Records (#145)—applies to commercial and Medicare Advantage
 - Clarifying that failure to submit timely records may result in claims denied as provider liability; providers cannot balance bill members for provider liability denials
 - Stating that we will no longer accept requested records after the 90-day courtesy deadline; providing records after this deadline will not change adjudication of the claim
 - Adding that to have records reviewed after the 90-day deadline, providers will need to follow the dispute process as stated in section 1.4 of the Appeals for Providers section of our [Administrative Manual](#)
- Virtual Care (#132)—applies to commercial
 - Removing HCPCS G2211 from this policy

Facility

- Emergency Department Visits: Level of Service (#110)—applies to commercial and Medicare Advantage
 - Removing American College of Emergency Physician (ACEP) guidelines
 - We will review these claims using Optum's Emergency Department Claim (EDC) Analyzer, which provides an ED visit-level analysis and code validation.

[View our Reimbursement Policy Manual](#)

Reimbursement policy feedback

We encourage physicians and other health care professionals to share their input using our [Reimbursement Policy Feedback Form](#).

Verify your provider information

Providing up-to-date and accurate information about the providers in each of our networks is critical for our members to access care, and it's a requirement for the Affordable Care Act (ACA) and Medicare Advantage plans.

Validating provider directory content

Practice information, including rosters, must be reviewed and validated in its entirety at least once every 90 days. [Follow these steps](#) to review the information about your practice.

- Respond timely to our requests for verification of your directory data.
- If your clinic or facility submits provider rosters to us, please send changes, corrections, additions or terminations immediately so we can update our directories as soon as possible.

We appreciate your assistance in keeping information about your practice up to date.

[Subscribe](#) | [Unsubscribe](#) | [Update preferences](#) | [Online privacy and security](#)

© 2025 Asuris P.O. Box 91130 Seattle, WA, 98111-9230, USA